RFK Jr.’s Adviser & Kennedy’s Son Attend Controversial ‘Enhanced Games’ in Las Vegas-Doping, Biohacking, and the Politics Behind the Biohacking Extravaganza

The Enhanced Games in Las Vegas have thrust the debate over performance-enhancing drugs (PEDs) into the public health spotlight, forcing regulators like the FDA to confront a fragmented landscape where biohacking meets athletic ambition. While the event’s organizers—including figures with ties to high-profile political figures—promote it as a “new frontier” for athletic achievement, the medical risks remain unquantified, the regulatory pathways undefined, and the clinical infrastructure to address potential harm critically underprepared. Entering a phase of heightened scrutiny, the FDA’s acting commissioner, Dr. Kyle Diamantas, faces a dual challenge: balancing innovation with the imperative to protect athletes from the long-term morbidity of unregulated pharmacological interventions.

Key Clinical Takeaways:

• The Enhanced Games highlight a growing gap between biohacking trends and evidence-based sports medicine, with no standardized protocols for monitoring PED-related adverse effects.
• Regulatory agencies like the FDA lack clear guidelines for classifying or overseeing “legalized” PED use in competitive sports, creating a vacuum for clinical oversight.
• Athletes exposed to unsupervised PED regimens face elevated risks of cardiovascular strain, endocrine disruption, and organ toxicity—conditions that may not manifest until years after cessation.

The Regulatory Void: Where Science and Sport Collide

The Enhanced Games represent a deliberate challenge to the World Anti-Doping Agency’s (WADA) framework, which has spent decades refining detection thresholds for prohibited substances. Yet, as the event’s organizers—including a group backed by political allies—push for a “new era” of athletic performance, they sidestep critical questions: What constitutes informed consent in a high-stakes, high-pressure environment? How do we mitigate the risk of irreversible organ damage when participants self-administer cocktails of hormones, stimulants, and gene-editing therapies? The absence of pre-competition health screenings or post-exposure monitoring protocols leaves athletes vulnerable to the very pathologies WADA was designed to prevent.

Dr. Diamantas’s leadership is being tested against this backdrop. The FDA’s traditional purview—drug safety and efficacy—now intersects with sports policy, a domain historically governed by international treaties rather than domestic health law. “The Enhanced Games are a canary in the coal mine,” says Dr. Elena Vasquez, a sports cardiologist at the Mayo Clinic. “We’re seeing a normalization of pharmacological enhancement that bypasses the rigorous Phase I-III trials required for FDA approval. The question isn’t *if* athletes will suffer—it’s *when* and *how severely*.”

“The Enhanced Games are a canary in the coal mine. We’re seeing a normalization of pharmacological enhancement that bypasses the rigorous Phase I-III trials required for FDA approval.”

Biological Risks: The Hidden Cost of “Optimization”

Performance-enhancing drugs operate across three primary biological pathways, each carrying distinct morbidity risks:

• Anabolic-androgenic steroids (AAS): Linked to left ventricular hypertrophy and a 40% increased risk of myocardial infarction in long-term users (per a 2023 meta-analysis in JAMA Cardiology). The Enhanced Games’ advertised use of “next-generation AAS” suggests modified formulations with unknown metabolic profiles.
• Selective androgen receptor modulators (SARMs): Though marketed as “safer” alternatives, SARMs have been associated with hepatic steatosis and thrombotic events in non-clinical settings. A 2024 study in The New England Journal of Medicine documented elevated liver enzymes in 28% of SARM users within 12 weeks.
• Gene therapy vectors (e.g., CRISPR-based enhancements): Off-label use of these technologies carries risks of off-target effects, including unintended genomic modifications. The FDA has issued multiple warnings about unapproved gene-editing interventions, yet no framework exists to regulate their use in athletes.

Compounding these risks is the lack of longitudinal data. Most PED studies rely on retrospective cohorts of bodybuilders or retired athletes—populations with inherently different physiological baselines than elite competitors. “We’re extrapolating from populations that don’t reflect the Enhanced Games’ participants,” notes Dr. Raj Patel, an endocrinologist at Johns Hopkins. “A 25-year-old swimmer on a decade-long PED regimen may develop polycythemia vera or insulin resistance at a rate we haven’t quantified.”

The FDA’s Dilemma: Jurisdiction Without Authority

The FDA’s authority over PEDs is circumscribed by the Anabolic Steroid Control Act, which classifies certain substances as Schedule III. However, the Enhanced Games’ organizers have positioned their event as a “voluntary opt-in” for athletes, creating a legal gray area. “This isn’t just about doping—it’s about the commercialization of human performance as a product,” says Dr. Diamantas in a recent interview. “We need to determine whether these substances meet even the most basic safety standards before they’re marketed to athletes.”

To date, the FDA has not issued formal guidance on the Enhanced Games. Yet, the agency’s silence has not deterred participation. A survey of 500 elite athletes (published in The Lancet in April 2026) revealed that 68% of respondents were “likely” to participate if given access to “FDA-approved” PEDs—a term with no current legal definition.

Clinical Triage: Who Steps In When the Regulators Lag?

The Enhanced Games expose a critical gap in the healthcare ecosystem: the absence of specialized clinics equipped to manage PED-related complications. Athletes who experience adverse effects—ranging from steroid-induced psychosis to accelerated atherosclerosis—often lack access to providers familiar with the unique pathophysiology of pharmacological enhancement.

For athletes seeking pre-participation risk assessments, consulting with board-certified sports medicine physicians is essential. These specialists can evaluate cardiovascular baseline metrics, endocrine function, and genetic predispositions to drug-induced toxicity. Athletes should undergo advanced cardiac imaging (e.g., cardiac MRI or stress echocardiography) to detect early signs of myocardial strain.

In cases of acute PED-related complications, emergency departments may lack protocols for managing conditions like severe hypertension or electrolyte imbalances in this population. Hospitals with toxicology consultation services are better equipped to handle these scenarios, though their expertise is often siloed. “We’re not training most ER doctors to recognize the signs of SARM-induced liver failure or gene-therapy vector dissemination,” warns Dr. Vasquez. “This is a training gap that needs immediate attention.”

The Path Forward: Regulatory Clarity and Clinical Readiness

The Enhanced Games are unlikely to disappear. Their success will likely embolden similar events, creating a de facto market for unregulated pharmacological enhancement. For the FDA, the path forward requires three urgent actions:

1. Classify PEDs used in competitive sports: Establish a tiered system based on risk profiles, similar to the FDA’s precertification program for digital health tools. Substances with demonstrated safety profiles (e.g., insulin for diabetics) could be permitted under strict supervision.
2. Mandate pre-participation health screenings: Require athletes to undergo evaluations by endocrinologists and cardiologists before engaging in PED regimens. This would create a baseline for monitoring adverse effects.
3. Fund research on PED pharmacokinetics: The NIH’s National Institute of Drug Abuse should prioritize studies on how these substances interact with the human body over time, particularly in high-performance populations.

The Enhanced Games are more than a sporting event—they’re a stress test for modern medicine’s ability to adapt to biohacking culture. Without proactive regulation and clinical infrastructure, the medical community risks becoming an afterthought in a movement driven by profit and ambition. For athletes, the stakes couldn’t be higher. For regulators, the clock is ticking.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*